

COVID ROOC

More Information Bank

Vaccines and Vaccinations

Note: Not all sources are peer-reviewed whereas some are reviews and interesting blogs. They are not intended in themselves to guide patient management decisions

[ACR Releases 2022 Vaccination Guideline Summary for Patients with RMDs \(August, 2022\)](#)

[Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease. \(August, 2022\)](#)

[Studies bolster evidence for COVID-19 vaccination in young people with RMDs. \(August, 2022\)](#)

[Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open label extension study. \(August, 2022\)](#)

[Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. \(August, 2022\)](#)

[SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. \(May, 2022\)](#)

[SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. \(May, 2022\)](#)

[Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort. \(May, 2022\)](#)

[Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? \(May, 2022\)](#)

[B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab. \(May, 2022\)](#)

[SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. \(April, 2022\)](#)

[Neutralizing immunity in vaccine breakthrough infections from SARS-CoV-2 Omicron and Delta variants. April, 2022\)](#)

[Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. \(April, 2022\)](#)

[COVID-19: Vaccines. \(April, 2022\)](#)

[American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. \(April, 2022\)](#)

[COVID-19 vaccination in patients with rheumatic diseases: Vaccination rates, patient perspectives, and side effects. \(March, 2022\)](#)

[Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever. \(March, 2022\)](#)

[Systemic Lupus Erythematosus and Antiphospholipid Syndrome After COVID-19 Vaccination. A Case Report. \(March, 2022\)](#)

[Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination. \(March, 2022\)](#)

[COVID-19 Vaccines: Myth Versus Fact. \(March, 2022\)](#)

[COVID-19 vaccines safe, effective in rheumatic diseases. \(February, 2022\)](#)

[Efficacy of COVID-19 vaccines in patients taking immunosuppressants. \(February, 2022\)](#)

[Ethics and Pitfalls of Vaccine Mandates. \(February, 2022\)](#)

[COVID-19 Vaccination Uptake among individuals with Immune-Mediated Inflammatory Diseases in Ontario, Canada between December 2020 and October 2021: A population-based analysis. \(January, 2022\)](#)

[Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. \(January, 2022\)](#)

[COVID-19 Vaccination Practice of Children with Rheumatic Disease: A Survey-based Study. \(January, 2022\)](#)

[COVID-19 Vaccination Intention and Vaccine Hesitancy among Patients with Autoimmune and Autoinflammatory Rheumatological Diseases: A Survey. \(January, 2022\)](#)

[Covid-19: Fourth vaccine doses—who needs them and why? \(January, 2022\)](#)

[Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. \(December, 2022\)](#)

[How Immunocompromised People without Strong Vaccine Protection Are Coping with COVID. \(November, 2021\)](#)

[Study Finds COVID-19 Vaccine Not Associated with Severe Disease Flare in Patients with Rheumatic Diseases. \(November, 2021\)](#)

[COVID-19 vaccines provide 5 times the protection of natural immunity, CDC study says. \(November, 2021\)](#)

[Booster augments COVID-19 vaccine response in patients on rituximab despite prior failures. \(November, 2021\)](#)

[ACR: COVID-19 Vaccine Not Tied to Severe Rheumatic Disease Flares. \(November, 2021\)](#)

[Survey: COVID-19 Vaccine Hesitancy Low Among People with Rheumatic Diseases \(October, 2021\)](#)

[Acceptability of Vaccines Against Preventable Infections Including Coronavirus Disease 2019 Among Patients With Rheumatic Disease \(October, 2021\)](#)

[American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: Version 3. \(October, 2021\)](#)

[ATAGI statement on the use of a 3rd primary dose of COVID-19 vaccine in individuals who are severely immunocompromised. \(October, 2021\)](#)

[Acceptability of Vaccines Against Preventable Infections Including Coronavirus Disease 2019 Among Patients with Rheumatic Disease. \(October, 2021\)](#)

[Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. \(October, 2021\)](#)

[Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. \(October, 2021\)](#)

[COVID-19 vaccine response varies widely among immunocompromised patients. \(September, 2021\)](#)

[Raynaud's Phenomenon after COVID-19 Vaccination: Causative Association, Temporal Connection, or Mere Bystander \(September, 2021\)](#)

[Covid-19 boosters to be offered starting September 20. \(August, 2021\)](#)

[Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases. \(August, 2021\)](#)

[American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: Version 3.\(August, 2021\)](#)

[Dermatology Patients on Biologics and Certain Other Systemic Therapies Should Receive a 'Booster' mRNA COVID-19 Vaccine Dose: A Critical Appraisal of Recent FDA and ACIP Recommendations. \(August, 2021\)](#)

[Delta variant of SARS-CoV-2 still transmissible for double jabbed. \(August, 2021\)](#)

[Pernio after COVID-19 vaccination. \(August, 2021\)](#)

[Outbreak of SARS-CoV-2 Infection, including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings, Barnstable County, Massachusetts, July 2021. \(August, 2021\)](#)

[FDA targets early September for COVID-19 booster strategy. \(August, 2021\)](#)

[CDC: Unvaccinated more than twice as likely to get COVID-19 reinfection. \(August, 2021\)](#)

[No higher risk of rheumatic and musculoskeletal disease flares seen after COVID-19 vaccination. \(August, 2021\)](#)

[Should the Lambda Variant Worry You? Not if You're Vaccinated. \(August, 2021\)](#)

[Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. \(July, 2021\)](#)

[Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. \(July, 2021\)](#)

[Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. \(July, 2021\)](#)

[Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. \(July, 2021\)](#)

[COVID-19 vaccine hesitancy still weighs heavy for some rheumatic disease patients. \(July, 2021\)](#)

[Herpes Zoster Following COVID-19 Vaccination. \(July, 2021\)](#)

[Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. \(July, 2021\)](#)

[Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. \(July, 2021\)](#)

[American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: Version 2. \(July, 2021\)](#)

[Anti-SARS CoV-2 mRNA vaccines in patients with rheumatoid arthritis. \(July, 2021\)](#)

[Flare of rheumatoid arthritis after COVID-19 vaccination \(July 1, 2021\)](#)

[B cell depletion impairs vaccination-induced CD8⁺ T cell responses in a type I interferon-dependent manner \(July, 2021\)](#)

[Timely second COVID shot especially important for rheumatoid arthritis patients \(July, 2021\)](#)

[WHO: COVID-19: Keep up with the latest safety and vaccine guidance \(July, 2021\)](#)

[Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military \(June, 2021\)](#)

[Post COVID-19 Lung Injury: What We Know So Far \(June, 2021\)](#)

[Pedro Machado, MD, PhD: COVID-19 Vaccine Safety in Patients With Rheumatic and Musculoskeletal Disease \(June, 2021\)](#)

[COVID Vaccine Safe in Rheumatic Patients \(June, 2021\)](#)

[ANTI-SARS-COV-2 MRNA vaccine in patients with rheumatoid arthritis \(June, 2021\)](#)

[COVID-19 vaccination advice via SMS-based video to improve vaccination uncertainty in at-risk groups \(June, 2021\)](#)

[Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases \(May, 2021\)](#)

[High antibody response to two-dose SARSCoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. \(May, 2021\)](#)

[LB0002 COVID-19 Vaccine Safety in Patients With Rheumatic And Musculoskeletal Disease. \(May, 2021\)](#)

[Number of COVID-19 vaccination doses administered in Europe as of May 31, 2021, by country \(May, 2021\)](#)

[Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants \(May, 2021\)](#)

[More Than Half of All American Adults Vaccinated as COVID Cases Ebb \(May, 2021\)](#)

[They Haven't Gotten a Covid Vaccine Yet. But They Aren't 'Hesitant' Either \(May, 2021\)](#)

[Lower SARS-CoV-2 Vaccine Responses Seen in Patients With Immune-Mediated Inflammatory Diseases \(May, 2021\)](#)

[Unvaccinated Shouldn't Rely on General COVID Protection \(May, 2021\)](#)

[ACR. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases \(May, 2021\)](#)

[Tips for Talking to Your Patients About Vaccination \(May, 2021\)](#)

[CDC. How to talk to your patients about COVID-19 vaccination \(May, 2021\)](#)

[Long Covid symptoms ease after vaccination, survey finds \(May, 2021\)](#)

[More Info on the J&J COVID-19 Vaccine Thrombosis Scare \(May, 2021\)](#)

[Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia \(May, 2021\)](#)

[Coronavirus vaccines may work in some people. It's because of their underlying conditions. \(May, 2021\)](#)

[Vaccination Rates Low Among Patients With Lupus on Medicaid \(May, 2021\)](#)

[Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort \(May, 2021\)](#)

[COVID vaccinations for individuals in Australia with rheumatology conditions. \(May, 2021\)](#)

[Herpes Zoster Following mRNA COVID-19 Vaccination in Patients With Autoimmune Inflammatory Rheumatic Diseases \(April, 2021\)](#)

[How mRNA Vaccines Could Prevent or Eliminate Infectious Diseases Beyond COVID-19 \(April, 2021\)](#)

[Pernio after COVID-19 vaccination. \(April, 2021\)](#)

[Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. \(April, 2021\)](#)

[The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis. \(April, 2021\)](#)

[COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach. \(April, 2021\)](#)

[Acute Allergic Reactions to mRNA COVID-19 Vaccines. \(April, 2021\)](#)

[Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. \(April, 2021\)](#)

[Counseling Immunocompromised Patients About the Johnson & Johnson/Janssen COVID-19 Vaccine \(April, 2021\)](#)

[Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 \(April, 2021\)](#)

[The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis \(April, 2021\)](#)

[COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach \(April, 2021\)](#)

[Pernio after COVID-19 Vaccination \(April, 2021\)](#)

[Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases \(April, 2021\)](#)

[COVID-19 Vaccination and Antirheumatic Disease Therapy. \(March, 2021\)](#)

[Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. \(March, 2021\)](#)

[Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey. \(March, 2021\)](#)

